Circulating Short-Chain Fatty Acids and Non-Alcoholic Fatty Liver Disease Severity in Patients with Type 2 Diabetes Mellitus. 2023

Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
Department of Family Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung 801, Taiwan.

(1) Background: Non-alcoholic fatty liver disease (NAFLD) is a major global health concern. The increasing prevalence of NAFLD has been related to type 2 diabetes mellitus (T2D). However, the relationship between short-chain fatty acids (SCFAs) and NAFLD severity is ambiguous in T2D subjects. This study aimed to explore the association of SCFAs with the severity of NAFLD in T2D patients. (2) Methods: We employed echography to examine the severity of hepatic steatosis. The serum levels of nine SCFAs, namely, formate, acetate, propionate, butyrate, isobutyrate, methylbutyrate, valerate, isovalerate, and methylvalerate, were measured using gas chromatography mass spectrometry. (3) Results: A total of 259 T2D patients was enrolled in this cross-sectional study. Of these participants, 117 with moderate to severe NAFLD had lower levels of formate, isobutyrate, and methylbutyrate than the 142 without NAFLD or with mild NAFLD. Lower circulating levels of isobutyrate and methylbutyrate were associated with an increased severity of NAFLD. A relationship between NAFLD severity and circulating isobutyrate and methylbutyrate levels was found independently of a glycated hemoglobin (HbA1C) level of 7.0%. (4) Conclusion: Circulating levels of isobutyrate and methylbutyrate were significantly and negatively correlated with NAFLD severity in the enrolled T2D patients. SCFAs may be related to NAFLD severity in T2D patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005232 Fatty Acids, Volatile Short-chain fatty acids of up to six carbon atoms in length. They are the major end products of microbial fermentation in the ruminant digestive tract and have also been implicated in the causation of neurological diseases in humans. Fatty Acids, Short-Chain,Short-Chain Fatty Acid,Volatile Fatty Acid,Acid, Short-Chain Fatty,Acid, Volatile Fatty,Fatty Acid, Short-Chain,Fatty Acid, Volatile,Fatty Acids, Short Chain,Short Chain Fatty Acid,Short-Chain Fatty Acids,Volatile Fatty Acids
D005234 Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. Liver Steatosis,Steatohepatitis,Steatosis of Liver,Visceral Steatosis,Liver Steatoses,Liver, Fatty,Steatohepatitides,Steatoses, Liver,Steatoses, Visceral,Steatosis, Liver,Steatosis, Visceral,Visceral Steatoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
November 2023, Liver international : official journal of the International Association for the Study of the Liver,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
November 2018, Cureus,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
March 2019, Nutrients,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
May 2022, Orvosi hetilap,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
May 2022, Orvosi hetilap,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
October 2022, Journal of clinical and translational hepatology,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
September 2014, Expert review of endocrinology & metabolism,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
January 2016, PloS one,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
January 2023, Annals of hepatology,
Hui-Ju Tsai, and Wei-Chun Hung, and Wei-Wen Hung, and Yen-Jung Lee, and Yo-Chia Chen, and Chun-Ying Lee, and Yi-Chun Tsai, and Chia-Yen Dai
January 2023, International journal of general medicine,
Copied contents to your clipboard!